AU
UK
CA
US
IND
NZ
Last update at 2026-06-18T20:28:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
Tue 13 May 25, 08:01 PMSpero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
Mon 28 Apr 25, 08:01 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -46.41500M | -89.75600M | -78.28000M | -60.92500M | -41.66200M |
| Minority interest | - | - | - | - | 0.35M |
| Net income | -48.02800M | -91.30100M | -77.51900M | -60.17500M | -41.66200M |
| Selling general administrative | 36.48M | 41.70M | 21.44M | 15.59M | 12.89M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 48.58M | 18.26M | 9.33M | 4.74M | 3.97M |
| Reconciled depreciation | 0.87M | 0.65M | 0.76M | 0.75M | 0.41M |
| Ebit | -42.19700M | -87.97100M | -79.87400M | -63.96600M | -43.21500M |
| Ebitda | -18.93700M | -87.37400M | -79.11300M | -63.21600M | -42.80600M |
| Depreciation and amortization | 23.26M | 0.60M | 0.76M | 0.75M | 0.41M |
| Non operating income net other | - | - | 0.83M | 2.29M | 1.14M |
| Operating income | -42.19700M | -87.97100M | -79.11300M | -63.21600M | -42.80600M |
| Other operating expenses | 79.15M | 106.23M | 88.44M | 67.96M | 42.81M |
| Interest expense | 2.60M | 1.94M | 0.00000M | 0.00000M | 0.30M |
| Tax provision | - | - | - | - | - |
| Interest income | 1.11M | 0.35M | 0.40M | 1.33M | 1.14M |
| Net interest income | -1.49900M | -1.59400M | 0.40M | 1.33M | 1.14M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.61M | 1.54M | -0.76100M | -0.75000M | 1.14M |
| Total revenue | 48.58M | 18.26M | 9.33M | 4.74M | 3.97M |
| Total operating expenses | 79.15M | 106.23M | 88.44M | 67.96M | 42.81M |
| Cost of revenue | - | - | - | 65.78M | 33.88M |
| Total other income expense net | -4.21800M | -1.78500M | 0.83M | 2.29M | 1.14M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -46.41500M | -89.75600M | -78.28000M | -60.92500M | -41.66200M |
| Net income applicable to common shares | -46.41500M | -89.75600M | -78.28000M | -60.92500M | -41.66200M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 182.39M | 124.80M | 171.07M | 153.45M | 106.10M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 4.18M | 3.38M | 8.83M | 6.06M | 4.82M |
| Total liab | 75.50M | 48.87M | 82.78M | 21.41M | 31.53M |
| Total stockholder equity | 106.89M | 75.93M | 88.29M | 132.04M | 74.57M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 6.94M | 8.97M | 14.35M | 12.24M | 21.59M |
| Common stock | 0.05M | 0.05M | 0.03M | 0.03M | 0.02M |
| Capital stock | 0.05M | 0.05M | 0.04M | 0.03M | 0.02M |
| Retained earnings | -391.07200M | -413.87800M | -367.46300M | -277.70700M | -199.42700M |
| Other liab | - | 22.26M | 58.14M | 0.18M | 0.25M |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 5.74M | 5.64M | 5.52M | 3.54M |
| Cash | 76.33M | 109.11M | 112.58M | 85.21M | 29.73M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 37.15M | 21.65M | 18.67M | 14.34M | 26.66M |
| Current deferred revenue | 27.11M | 10.37M | 1.86M | - | - |
| Net debt | -70.79000M | -102.46000M | -105.24900M | -77.37100M | -24.18500M |
| Short term debt | 1.72M | 1.69M | 1.36M | 0.95M | 0.93M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 5.54M | 6.65M | 7.33M | 7.84M | 5.54M |
| Other stockholder equity | 497.91M | 489.76M | 455.72M | 409.72M | 273.97M |
| Property plant equipment | - | 5.49M | 7.56M | 1.67M | 7.15M |
| Total current assets | 131.21M | 109.11M | 157.87M | 126.91M | 82.05M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 75.93M | 88.29M | 132.04M | 74.57M |
| Short term investments | - | 0.00000M | 33.82M | 41.70M | 52.31M |
| Net receivables | 50.70M | 1.08M | 2.64M | 6.18M | 8.55M |
| Long term debt | - | - | - | 0.18M | 0.25M |
| Inventory | 0.00000M | -4.46300M | -0.36100M | -12.23900M | -13.36900M |
| Accounts payable | 1.38M | 0.62M | 1.10M | 1.16M | 4.15M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -0.00200M | -0.00700M | 0.02M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.03M | 0.02M |
| Preferred stock total equity | - | - | - | 0.00300M | - |
| Retained earnings total equity | - | - | - | -277.70700M | -199.42700M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.43M | 10.20M | 5.64M | 17.76M | 16.91M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 51.18M | 15.70M | 13.20M | 26.55M | 24.06M |
| Capital lease obligations | 5.54M | 6.65M | 7.33M | 7.84M | 5.54M |
| Long term debt total | - | - | - | 0.18M | 0.25M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 33.81M | 7.67M | 10.63M | 29.84M | -80.72000M |
| Change to liabilities | 21.41M | 10.59M | -12.17700M | 14.12M | 3.66M |
| Total cashflows from investing activities | 33.81M | 7.67M | 10.47M | 29.53M | -83.15600M |
| Net borrowings | -54.48500M | -54.48500M | -54.48500M | -54.48500M | - |
| Total cash from financing activities | -29.55300M | 84.05M | 130.88M | 16.14M | 69.52M |
| Change to operating activities | -0.86800M | -1.56000M | -12.66500M | 13.30M | -2.56000M |
| Net income | -46.41500M | -89.75600M | -78.28000M | -60.92500M | -41.66200M |
| Change in cash | -3.47700M | 27.38M | 55.48M | -4.35000M | -53.25800M |
| Begin period cash flow | 112.58M | 85.21M | 29.73M | 34.08M | 87.34M |
| End period cash flow | 109.11M | 112.58M | 85.21M | 29.73M | 34.08M |
| Total cash from operating activities | -7.73100M | -64.34700M | -85.87200M | -50.02000M | -39.62500M |
| Issuance of capital stock | 24.51M | 35.37M | 129.65M | 15.79M | 70.50M |
| Depreciation | 0.87M | 0.65M | 0.76M | 0.75M | 0.41M |
| Other cashflows from investing activities | - | - | - | 29.84M | -80.72000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 1.20M | 3.05M | 2.43M | -7.38400M | 0.64M |
| Sale purchase of stock | 10.28M | 27.54M | 14.18M | 16.14M | 69.52M |
| Other cashflows from financing activities | -64.34300M | 21.14M | 52.22M | 0.35M | -0.97700M |
| Change to netincome | 15.73M | 11.90M | 4.56M | 3.72M | 3.37M |
| Capital expenditures | 0.00000M | 0.04M | 0.16M | 0.31M | 2.44M |
| Change receivables | - | - | 2.18M | -7.08500M | 1.41M |
| Cash flows other operating | - | - | -2.87800M | 0.15M | -6.13500M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | 55.48M | -4.35000M | -53.25800M |
| Change in working capital | 22.09M | 12.90M | -13.39200M | 6.83M | -1.07100M |
| Stock based compensation | 9.12M | 9.43M | 4.89M | 3.78M | 2.75M |
| Other non cash items | 6.61M | 2.37M | 0.51M | 0.36M | -0.05000M |
| Free cash flow | -7.73100M | -64.30800M | -86.02900M | -50.33400M | -42.06100M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SPRO Spero Therapeutics Inc |
0.17 8.06% | 2.28 | 3.28 | - | 0.85 | 0.83 | 0.18 | 0.69 |
| NVO Novo Nordisk A/S |
-0.33 0.76% | 43.19 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.18 2.68% | 42.83 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-7.36 1.60% | 451.63 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.01 0.33% | 609.94 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
675 Massachusetts Avenue, Cambridge, MA, United States, 02139
| Name | Title | Year Born |
|---|---|---|
| Dr. Ankit Mahadevia M.D., MBA | Co-Founder, Pres, CEO & Director | 1981 |
| Mr. Satyavrat Shukla C.F.A. | CFO & Treasurer | 1972 |
| Ted Jenkins | VP & Head of Investor Relations | NA |
| Ms. Tamara Lynn Joseph L.L.M. | Chief Legal Officer | 1963 |
| Mr. James P. Brady | Chief Human Resource Officer | NA |
| Mr. Timothy Keutzer | Chief Devel. Officer | 1968 |
| Dr. Ian A. Critchley | Head of Clinical Microbiology | NA |
| Dr. Susannah Walpole Ph.D. | Head of Clinical Operations | NA |
| Dr. Angela Talley M.D. | Sr. VP of Clinical Devel. | NA |
| Dr. Kamal Hamed M.B.A., M.D., M.P.H. | Chief Medical Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...